Eli Lilly & Co. - LLY STOCK NEWS

Eli Lilly (NYSE: LLY) will attend the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020. Michael Mason, the senior vice president, will engage in a virtual fireside chat at 2:40 p.m. ET. Investors can access the live audio webcast through the 'Webcasts & Presentations' section of Lilly's Investor website, with a replay available for 90 days following the event. Founded over a century ago, Lilly is committed to creating high-quality medicines and improving disease management worldwide.

Health Canada has authorized bamlanivimab (LY-CoV555) for treating adults and pediatric patients (12+) with mild to moderate COVID-19 at high risk of severe illness. This authorization is based on BLAZE-1 trial data, showing reduced viral load and symptom rates. Lilly plans to manufacture up to one million doses by year-end 2020 and is pursuing additional global authorizations. While the FDA granted Emergency Use Authorization for bamlanivimab in the U.S., it remains unapproved for any use, emphasizing the need for careful monitoring of its safety and efficacy.

Eli Lilly and Incyte announced that the FDA granted an Emergency Use Authorization (EUA) for baricitinib in combination with remdesivir for hospitalized patients with COVID-19 requiring supplemental oxygen. This is the second Lilly therapy to receive EUA for COVID-19 treatments. In clinical trials, the combination showed a 12.5% reduction in recovery time and a 35% decrease in mortality compared to remdesivir alone. Despite this progress, the use remains temporary, pending further evaluation of baricitinib's efficacy and safety.

Eli Lilly and Ypsomed have entered a global agreement to develop an automated insulin delivery system. Lilly will commercialize a version of Ypsomed's mylife™ YpsoPump®, already marketed in Europe since 2016. This system will also incorporate continuous glucose monitoring and utilize pre-filled cartridges for Lilly's rapid-acting insulins. Ypsomed aims for FDA clearance in 2022. With diabetes affecting over 34 million Americans, this partnership seeks to enhance diabetes management options.

The EMPA-REG OUTCOME trial results reveal that Jardiance (empagliflozin) significantly reduces the risk of total cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.

Compared to placebo, Jardiance decreased the relative risk of 3P-MACE by 22%, heart failure hospitalizations by 42%, and all-cause hospitalizations by 17%. These findings underscore the long-term cardiovascular benefits of Jardiance and the ongoing commitment of Boehringer Ingelheim and Eli Lilly to enhance health outcomes in this patient population.

Eli Lilly and Company (NYSE: LLY) is set to participate in the Wolfe Research Virtual Healthcare Conference on November 18, 2020. Joshua Smiley, the company's CFO, will engage in a virtual fireside chat at 1:30 p.m. ET. Investors and interested parties can access a live audio webcast through the Webcasts & Presentations section of Lilly's Investor website, with a replay available for 90 days following the event.

Lilly aims to enhance global healthcare through innovative medicines and community engagement.

Eli Lilly and Company (NYSE: LLY) will join the Bernstein Operational Decisions Conference on November 16, 2020. Key executives, including Andrew Adams and Jeff Emmick, will engage in a virtual fireside chat at 11:00 a.m. ET. A live audio webcast can be accessed via Lilly's Investor website, with a replay available for 90 days. Lilly is committed to advancing healthcare by developing innovative medicines and enhancing disease management. For more details, visit www.lilly.com.

Eli Lilly and Company (NYSE: LLY) will host a webcast on November 20, 2020, at 11:00 a.m. EST, to discuss the Phase 3 clinical trial program for tirzepatide, aimed at treating type 2 diabetes. The session will cover trial designs and the expected schedule for multiple top-line data disclosures. Investors, media, and the public can access the webcast via Lilly's investor website, with a replay available afterwards. The announcement emphasizes Lilly's ongoing commitment to developing effective treatments, while recognizing the uncertainties involved in pharmaceutical research.

The FDA has granted Emergency Use Authorization (EUA) to Eli Lilly's investigational neutralizing antibody, bamlanivimab (LY-CoV555) 700 mg, for treating mild to moderate COVID-19 in patients aged 12 and older who are at high risk of severe illness. Administered via a single intravenous infusion, bamlanivimab is designed to be given within 10 days of symptom onset. This authorization is based on data from the BLAZE-1 clinical trial, which showed significant reduction in viral load and related hospitalizations. The U.S. government has purchased 300,000 doses to ensure accessibility.